Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Daiichi Sankyo
Fuji
Deloitte
Merck
Boehringer Ingelheim
McKinsey
Baxter
Queensland Health
Mallinckrodt

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,762,180

« Back to Dashboard

Which drugs does patent 6,762,180 protect, and when does it expire?

Patent 6,762,180 protects OFEV and is included in one NDA.

This patent has fifty-six patent family members in forty-one countries.
Summary for Patent: 6,762,180
Title: Substituted indolines which inhibit receptor tyrosine kinases
Abstract:Indolinones of the formula ##STR1## having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are: (a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycar bonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoy l-2-indolinone, and (c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxyca rbonyl-2-indolinone.
Inventor(s): Roth; Gerald Juergen (Biberach, DE), Heckel; Armin (Biberach, DE), Walter; Rainer (Biberach, DE), Van Meel; Jacobus (Moedling, AT), Redemann; Norbert (Biberach, DE), Tontsch-Grunt; Ulrike (Baden, AT), Spevak; Walter (Oberrohrbach, AT), Hilberg; Frank (Vienna, AT)
Assignee: Boehringer Ingelheim Pharma KG (Ingelheim, DE)
Application Number:09/678,682
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 6,762,180

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-002 Oct 15, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,762,180

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 49 208Oct 13, 1999
Germany100 42 696Aug 31, 2000

International Patents Family Members for US Patent 6,762,180

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2387013 ➤ Subscribe
China 1391557 ➤ Subscribe
China 100455568 ➤ Subscribe
Colombia 5261488 ➤ Subscribe
Cyprus 1110067 ➤ Subscribe
Czech Republic 301073 ➤ Subscribe
Germany 10042696 ➤ Subscribe
Germany 19949208 ➤ Subscribe
Germany 50015711 ➤ Subscribe
Eurasian Patent Organization 006080 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo
Harvard Business School
Baxter
Healthtrust
Moodys
Deloitte
Cantor Fitzgerald
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot